MYCO-002
Pharmaceutical compound
From Wikipedia, the free encyclopedia
MYCO-002 is an MDMA-like entactogen that is under development for the treatment of psychiatric disorders.[1][2][3] It is said to be being developed towards the aim of improving the safety profile of MDMA.[3] The drug is under development by Mydecine.[1][2] It was patented in July 2021 and received breakthrough therapy designation from the Food and Drug Administration (FDA) in November 2021.[1] As of November 2021, MYCO-002 is in the preclinical research for treatment of psychiatric disorders.[1][2] The chemical structure of MYCO-002 does not yet appear to have been disclosed.[1][2]
Other namesMYCO002
| Clinical data | |
|---|---|
| Other names | MYCO002 |
| Drug class | Entactogen; Empathogen |
